NCT02770261View on ClinicalTrials.gov

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

October 31, 2016

Conditions
HypertensionCholesterolemia
Interventions
DRUG

DP-R208

DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo

DRUG

Candesartan32mg

DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

DRUG

Rosuvastatin 20mg

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

DP-R208 Placebo

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

Candesartan32mg Placebo

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

Rosuvastatin 20mg Placebo

DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY

NCT02770261 - Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy | Biotech Hunter | Biotech Hunter